We use the power of science to deliver needed new medicines to patients
We operate with the long-term outlook required to turn rigorous scientific research into important new medicines. As a result of this focus on R&D, all of our approved medicines were homegrown in our laboratories. Our support for patients extends beyond the lab to disease education and awareness efforts, product support services and our commitment to access and responsible pricing.
Our robust pipeline spans eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.See what’s in the pipeline
We are intent on deepening our strong and sustainable portfolio of innovative medicines. We are improving the traditional drug development process through proprietary technologies that accelerate the time from discovery to drug approval and improve the likelihood of success. We are also leading ambitious initiatives, such as the Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.EXPLORE OUR TECHNOLOGIES
We are motivated by the desire to deliver new medicines for people in need – and we want to make sure people can access and afford those medicines regardless of their background or geography. We are committed to developing pricing approaches that facilitate patient access and foster medical innovation through engagement with our stakeholders.
Read page 36 of our 2020 Responsibility Report for our case study on providing access to low- and middle-income countries
Product support programs
We help make our products more accessible through our product support programs. These programs, for example, help healthcare providers and patients navigate health insurance plans and offer co-pay support to eligible commercial patients.
We also provide patient assistance programs that are designed to increase access to medicine and provide education on using medicines safely and appropriately. Our programs help eligible patients throughout their treatment journey with insurance eligibility support, patient resources, financial assistance and access to free medicine.
Compassionate Use: access to investigational medicines
Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval.
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our Compassionate Use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.
Patient assistance foundations
We are committed to ensuring that patients can afford and remain compliant with the therapy that best suits their medical needs. We donate to independent third-party charitable foundations, known as Patient Assistance Foundations, which provide financial assistance to patients who might not otherwise be able to afford their medications. Our charitable contributions support patients without regard to the beneficiary’s choice of product, provider, practitioner, supplier or health plan. We provide guidelines and training to our colleagues who might engage with the Foundations, and we review our activities throughout the year to ensure our guidelines are followed.
Increasing disease awareness
We believe patients should be knowledgeable about their disease so they can advocate and make informed decisions around their care. Regeneron supports efforts to empower patients with information to help them better understand and manage their disease. We support organizations that create educational materials and disease management tools for patients and their caregivers. We know that patients are seeking information from the most trusted sources and we want to ensure that there is up-to-date and relevant information wherever they look.
Elevating the patient voice
We recognize that patient advocacy groups represent their respective patient communities’ needs, issues and challenges and can also help to raise awareness, empower patients through education and advocate for patients to receive the best care. We aim to develop meaningful, long-term relationships with patient advocacy groups and to collaborate on addressing important health issues that result in positive patient outcomes.
Supporting patient access
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes. To submit a request for funding, visit our grants portal.
Read pages 29 - 31 of our 2020 Responsibility Report to learn how we put our patient advocacy into action.
We are always looking for ways to make the drug discovery process faster and more efficient, especially in scenarios where help is desperately needed. To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite® technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments extremely quickly. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.
Unfortunately, COVID-19 will not be the last pandemic or epidemic the world faces. This is why we see particular utility in building our core technologies, conducting deep biological research and investing in large-scale manufacturing infrastructure for antibody treatments and vaccines. We are committed to doing what’s right and we believe applying our resources and expertise to combat dangerous pathogens is crucial to our mission to improve lives through science.
"What can we do to help?"
During the 2014 West African Ebola outbreak, our team was reading increasingly concerning reports and began asking one another, “What can we do to help?” Our eagerness to get involved led to a realization that we could, for the first time, apply our technologies to develop a novel antibody treatment for a deadly viral pathogen, and, potentially help address a daunting global health challenge.
We applied these core technologies to generate potent Ebola-neutralizing antibodies at an unprecedented speed and selected a cocktail of three complementary antibodies, condensing a process that normally takes years into less than 12 months. Thankfully, the 2014-2015 outbreak ended before our investigational compound entered clinical trials, and we instead focused on preclinical and early research to confirm safety in humans. When a new outbreak began in the Democratic Republic of the Congo in 2018, we were ready. We moved quickly to have our investigational medicine made accessible through a compassionate use protocol and included in an independently run clinical trial to test safety and efficacy.
Data from this trial ultimately supported the U.S. Food and Drug Administration’s approval of our antibody cocktail on Oct. 14, 2020.
Moving at pandemic speed
When the novel coronavirus, SARS-CoV-2, began to spread globally in early 2020, our team asked again, “What can we do to help?” Building on prior experience, Regeneron scientists applied the same VelociSuite® technologies and examined antibodies derived from human survivors of the disease to rapidly develop a large pool of antibody candidates capable of neutralizing the virus. The team selected a potent, tightly-binding, non-competing pair and began exploring the cocktail’s potential to be used as a preventative or treatment for COVID-19. Improving on our prior infectious disease timeline, this combination was ready to enter human clinical trials just five months after we first accessed the SARS-CoV-2 viral sequence.
As part of our rapid response approach and in recognition of the tremendous global need, we simultaneously initiated clinical trials and our large-scale manufacturing process. Manufacturing biologic medicines like antibodies is a time-consuming and precise process, and unfortunately biology can’t be hurried along. Despite the risks and uncertainties, we purposefully began this effort as early as possible so that we would have as many doses as possible immediately available for people around the world.
To further increase access, we have also joined forces with Roche to develop and manufacture our COVID-19 treatment.
On November 21, 2020 our COVID-19 antibody cocktail was granted an Emergency Use Authorization (EUA) by the FDA, the first combination therapy to receive an EUA and in record time – only ten months after the program inception.
Our collaboration with Roche is expected to significantly increase global supply and hopefully provide the world with a critical line of defense against the COVID-19 pandemic.
Nilda’s COVID-19 Journey
Hear one woman’s experience with COVID-19, and how she decided to act quickly following diagnosis to see if treatment was right for her.